| Previous Close | 11.85 |
| Open | 11.56 |
| Bid | 11.56 x 900 |
| Ask | 11.57 x 1800 |
| Day's Range | 11.31 - 11.75 |
| 52 Week Range | 11.31 - 17.62 |
| Volume | 1,652,756 |
| Avg. Volume | 2,444,512 |
| Market Cap | 2.179B |
| Beta (3Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / U.S. markets bounced on Friday, erasing some of the losses for the week, as the third quarter earnings season kicked off. The Dow Jones Industrial Average ...
Management and External Thought Leaders to HighlightRobust Portfolio of Novel Therapies for Rare Metabolic Diseases Webcast Scheduled from 8:30am – 12:30pm E.T. CRANBURY,.
Amicus Therapeutics (FOLD) today announced a major collaboration with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania (Penn) to pursue research and development of novel gene therapies for Pompe disease, Fabry disease, CDKL5 deficiency and one additional undisclosed rare metabolic disorder. This relationship will combine Amicus’ protein engineering and glycobiology expertise with Penn’s adeno associated virus (AAV) gene transfer technologies to develop AAV gene therapies designed for optimal cellular uptake, targeting, dosing, safety and manufacturability.
Amicus Therapeutics (FOLD) today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in patients with Pompe disease, an inherited lysosomal storage disorder caused by an enzyme deficiency that leads to accumulation of glycogen (disease substrate) in cells. Patients treated with AT-GAA for up to 18 months showed improvements in six-minute walk test (6MWT) distance and other measures of motor function and muscle strength, stability or increases in forced vital capacity (FVC), and durable reductions in biomarkers of muscle damage and disease substrate.
CRANBURY, N.J., Oct. 02, 2018 -- Amicus Therapeutics (Nasdaq:FOLD), today announced that an oral presentation and a poster highlighting its development program AT-GAA for Pompe.
NEW YORK, NY / ACCESSWIRE / September 27, 2018 / U.S. markets fell sharply Wednesday after the Federal Reserve raised interest rates and indicated another increase would be coming in December. The Nasdaq Composite Index decreased 0.21 percent to close at 7,990.37. “It was virtually a foregone conclusion, and that may cause some investors to scratch their heads a bit given all the uncertainty in the market, with trade barbs flying, an unstable housing market, and ballooning federal debt,” according to Mike Loewengart, vice president of investment strategy at E-Trade Financial Corp. “But the Fed needs to build up its toolbox to address a variety of economic conditions, which makes getting back to a normalized rate environment so important.
CRANBURY, N.J., Sept. 26, 2018-- Amicus Therapeutics today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview and fireside chat at the Leerink Partners ...
NEW YORK, Sept. 25, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
License with Nationwide Children’ s Hospital through the Acquisition of Celenex Establishes Amicus as Leading Gene Therapy Company in Neurologic Lysosomal Storage Disorders with Potential to Transform ...
CRANBURY, N.J., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the appointment of Lynn D. Bleil to its Board of Directors, effective immediately. Amicus also announced that current Director Michael G. Raab has been named Lead Independent Director.
NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Wall Street plunged on Friday after the Trump administration announced tariffs on another $267 billion worth of Chinese goods, pressuring the S&P 500 and ...
During the third quarter, Amicus held a Type C meeting with the United States Food and Drug Administration (FDA) in order to discuss the regulatory path for AT-GAA. Specifically, Amicus sought input on the design of a pivotal study for full approval for AT-GAA, other supplemental clinical studies in Pompe disease patients, and whether Amicus may pursue an Accelerated Approval pathway in the United States at this time.
CRANBURY, N.J., Aug. 31, 2018-- Amicus Therapeutics today announced upcoming presentations at two investor conferences in September.. Bradley Campbell, President and Chief Operating Officer, and Chip Baird, ...
Amicus Therapeutics (FOLD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Galafold™ (migalastat) 123 mg capsules. Galafold is an oral, precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.
2 Q18 Net Product Sales of $21.3 M Driven by Galafold ® Expansion. Company Increases FY18 Global Galafold Revenue Guidance to $80 M- $90 M. Pompe Clinical, Regulatory and Manufacturing Activities Continue ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Amicus Therapeutics, Inc. (NASDAQ: FOLD ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern ...
NEW YORK, July 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amicus ...
CRANBURY, N.J., July 31, 2018-- Amicus Therapeutics today announced that the Company will host a conference call and live audio webcast on Tuesday, August 7, 2018 at 8:30 a.m. ET to discuss financial results ...
NEW YORK, NY, July 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders ...
Stock Research Monitor: HEB, HTBX, and PBYI LONDON, UK / ACCESSWIRE / July 30, 2018/ If you want a free Stock Review on FOLD sign up now at www.wallstequities.com/registration . On Friday, benchmark US ...
LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday's trading session in bullish territories.
NEW YORK, NY / ACCESSWIRE / June 27, 2018 / U.S. markets rebounded on Tuesday after experiencing steep losses the past week due to growing trade tensions. The Dow Jones Industrial Average increased 0.12 ...